NASDAQ$ZNTL
Zentalis Pharmaceuticals Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Reported first quarter 2023 financial results and provided operational updates.
Zentalis Pharmaceuticals reported a cash balance of $392 million as of March 31, 2023, with a projected cash runway into the second quarter of 2025. The company is on track to disclose monotherapy dose and updates on accruing trials for azenosertib in 1H 2023 and will present positive Phase 1b azenosertib + chemotherapy clinical data in ovarian cancer at ASCO.
- On track to disclose monotherapy dose and updates on currently accruing trials for azenosertib in 1H 2023.
- Positive Phase 1b azenosertib + chemotherapy clinical data in ovarian cancer to be presented at the 2023 ASCO Annual Meeting.
- Announced collaborations with Foundation Medicine and Roche Diagnostics to advance the development of azenosertib.
- Appointed Diana Hausman, M.D. to Board of Directors and Funda Meric-Bernstam, M.D. to Scientific Advisory Board.
Headline financials
Revenue & EPS history
Zentalis · Revenue · Quarterly
$0
Forward guidance
Zentalis believes that its existing cash, cash equivalents and marketable securities as of March 31, 2023 will be sufficient to fund its operating expenses and capital expenditure requirements into the second quarter of 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2023
-1.7%
Avg return
Earnings day
-2.2%
Avg return
5 days after
+2.4%
Avg return
30 days after
58%
14 / 24 earnings
Positive
+14.5%
Q1 2023
Best reaction
-43.0%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.9% | -1.7% | — | |
| Q4 2025 | +3.1% | -3.7% | +49.1% | |
| Q3 2025 | +6.2% | +0.8% | +9.8% | |
| Q1 2025 | -2.5% | +3.3% | +10.7% | |
| Q4 2024 | -12.6% | -15.0% | -23.5% | |
| Q3 2024 | -2.7% | -13.9% | -22.3% | |
| Q2 2024 | -8.8% | -12.5% | -10.6% | |
| Q1 2024 | +6.1% | +7.0% | -5.5% | |
| Q4 2023 | +10.0% | +8.5% | +11.9% | |
| Q3 2023 | -43.0% | -45.0% | -33.1% | |
| Q2 2023 | +5.3% | +11.2% | -0.5% | |
| Q1 2023 | +14.5% | +22.8% | +2.7% | |
| Q4 2022 | +1.2% | -2.1% | -9.1% | |
| Q3 2022 | -14.1% | -4.3% | -17.4% | |
| Q2 2022 | -0.1% | -7.3% | -8.1% | |
| Q1 2022 | -16.4% | -24.7% | +1.3% | |
| Q4 2021 | +7.6% | +5.7% | -3.2% | |
| Q3 2021 | +0.8% | -1.0% | -8.8% | |
| Q2 2021 | +4.9% | +7.1% | +39.0% | |
| Q1 2021 | -4.6% | -1.3% | -9.0% | |
| Q4 2020 | +1.4% | -0.7% | +45.7% | |
| Q3 2020 | -5.6% | -2.1% | +36.3% | |
| Q2 2020 | +1.0% | +7.2% | -10.6% | |
| Q1 2020 | +4.5% | +8.2% | +10.5% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro